SEC Backs CFTC Approval of U.S. Single-Stock Perpetual Futures

The SEC has filed an amicus brief backing the CFTC's approval of U.S. single-stock perpetual futures, siding with its fellow regulator as challengers try to overturn the decision in court.

The filing disputes the claim that the Commodity Futures Trading Commission exceeded its statutory authority when it approved the products. According to the SEC, the CFTC's related rule changes were subject to SEC review — a position that directly undercuts the challengers' core argument that the derivatives regulator acted alone and outside its lane.

The brief also states that the two commissions are cooperating on oversight of single-stock perpetual derivatives. The SEC links that cooperation, and its own review role, to the CFTC's approval authority, placing coordination between the two agencies at the heart of its legal defense.

What does this change for the products?

For issuers and trading venues, the SEC's intervention matters because it signals a unified federal front. If a court accepted the challengers' argument — that the CFTC overstepped — the approval could be vacated, and the U.S. market for single-stock perpetuals would face an uncertain restart. Instead, the SEC has now put its own review authority on record as part of the approval process.

That framing has practical weight. It suggests both agencies view the products as jointly supervised instruments rather than the exclusive province of one regulator, which shapes how future rule changes for perpetual-style equity derivatives will be handled.

Why the dispute exists

Single-stock perpetual futures are a hybrid instrument: futures-style contracts without fixed expiry dates, closer in behavior to perpetual swaps. Their approval by the CFTC opened a new corner of the U.S. derivatives market, and challengers responded by taking the decision to court.

The SEC's amicus brief addresses two points at once. First, it defends the CFTC's power to approve the products at all. Second, it asserts that the CFTC's related rule changes fell within the SEC's own review scope — meaning the approval was not a unilateral act but one layered with securities-side scrutiny.

The bigger picture

Regulatory turf between the SEC and CFTC has long defined U.S. market structure, and disputes over who controls a given instrument often stall product launches for years. Here the dynamic runs the other way. The SEC is using a court filing to describe active cooperation with the CFTC on oversight of the very products under challenge.

That cooperation is not incidental to the SEC's argument. The brief ties the joint oversight work to the CFTC's approval role, presenting a coordinated regulatory framework as evidence the products sit within lawful bounds.

The court now weighs the challengers' claim that the CFTC exceeded its authority against this two-agency defense. The outcome will determine whether the approval stands and whether jointly reviewed perpetual equity derivatives gain a durable footing in the U.S. market.